



(51) International Patent Classification:

A61K 47/55 (2017.01)

(21) International Application Number:

PCT/IB2024/055751

(22) International Filing Date:

12 June 2024 (12.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/508,039 14 June 2023 (14.06.2023) US
63/555,128 19 February 2024 (19.02.2024) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85, Södertälje (SE).

(72) Inventors: **LEE, Esther Cheng Yin**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **GOPALSAMY, Ariamala**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **SCHNEIDER, Michael**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **REICHL, Kyle David**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **MARCYK, Paul Tomas**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **REIMANN, Christopher Elias**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **CALIMAN, Alisha Danielle**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **WALTON, Laura**; ASTRAZENECA INTELLECTUAL PROPERTY, Eastbrook House, Shaftesbury Road, Cambridge Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: SMARCA2 DEGRADERS AND USES THEREOF



(A)

(57) Abstract: The present disclosure provides compounds represented by Formula (A), or a pharmaceutically acceptable salt and/or stereoisomer thereof: (A), wherein R^a , R^b , R^7 , R^8 , R^9 , R^{10} , R^{12} , R^{12a} , R^{12b} , R^{12c} , m , X^3 , W , L , and E are as defined in the specification. Compounds represented by Formula (A) are SMARCA2 protein degraders and are thus useful for treating cancer and other diseases.